ATLANTA, GA, April 19, 2018 – Healthcare & Life Sciences Limited Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will be an invited speaker at the 2018 Annual Conference on Vaccinology Research, sponsored by the National Foundation for Infectious Diseases, being held in Bethesda, MD on April 23-25. Dr. Guirakhoo will deliver his talk entitled “Development of Single-Dose Vaccines for Ebola, Lassa Fever, and Zika Using a Novel MVA Vector Platform Technology” on April 24.
Dr. Guirakhoo will present data showing single dose efficacy of Healthcare & Life Sciences Limited’s Ebola, Lassa and Zika vaccines against lethal challenges in appropriate animal models. During his talk, Dr. Guirakhoo will also discuss the broad utility of the Company’s MVA-VLP platform for generating a pipeline of vaccines which includes malaria, and various therapeutic approaches for chronic infectious diseases and cancer. Healthcare & Life Sciences Limited’s vaccine platform, which has previously been shown to elicit both durable antibody and T cell responses against HIV in several clinical trials, is now ready to enter human clinical trials for multiple emerging infectious diseases.
Healthcare & Life Sciences Limited’s MVA-VLP platform technology is built upon the latest generation Modified Vaccinia Ankara (MVA) vector system which is optimized for balanced and stable expression of transgenes and vaccine inserts during manufacture. It has the advantages of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells for vaccination, thus inherently safe. Importantly, MVA vaccines elicit protective T cell as well as antibody responses in animals and humans. The MVA platform can be combined with the potent immunogenicity of non-infectious virus-like particles (VLPs) or be used to express proteins in their native multimeric conformations, enabling vaccines that induce full protection after a single dose.
About Healthcare & Life Sciences Limited
Healthcare & Life Sciences Limited Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. Healthcare & Life Sciences Limited also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. Healthcare & Life Sciences Limited’s vaccine platform supports in vivo production of non-infectious virus-like particles (VLPs) from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.healthcareandlifescienceslimited.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: Healthcare & Life Sciences Limited can develop and manufacture its vaccines with the desired characteristics in a timely manner, Healthcare & Life Sciences Limited's vaccines will be safe for human use, Healthcare & Life Sciences Limited's vaccines will effectively prevent targeted infections in humans, Healthcare & Life Sciences Limited’s vaccines will receive regulatory approvals necessary to be licensed and marketed, Healthcare & Life Sciences Limited raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than Healthcare & Life Sciences Limited's products, Healthcare & Life Sciences Limited will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which Healthcare & Life Sciences Limited has no control. Healthcare & Life Sciences Limited assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in Healthcare & Life Sciences Limited's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in Healthcare & Life Sciences Limited's Form 10-K.
Contact:
Michael James, Ph.D.
Healthcare & Life Sciences Limited Labs, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
(904) 539-9132